OTCMKTS:PPCBPropanc Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.0030 0.00 (0.00 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.00Now: $0.00▼$0.0050-Day Range$0.00MA: $0.01▼$0.0152-Week Range$0.00Now: $0.00▼$3.05Volume19.16 million shsAverage Volume20.04 million shsMarket Capitalization$141,270.00P/E RatioN/ADividend YieldN/ABeta2.98 ProfileAdvanced ChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company's lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. Propanc Biopharma, Inc. has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Propanc Biopharma. Previous Next 3.3 Community Rank Outperform VotesPropanc Biopharma has received 85 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPropanc Biopharma has received 44 “underperform” votes. (Add your “underperform” vote.)Community SentimentPropanc Biopharma has received 65.89% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Propanc Biopharma and other stocks. Vote “Outperform” if you believe PPCB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PPCB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPropanc Biopharma does not currently pay a dividend.Dividend GrowthPropanc Biopharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Propanc Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.25% of the stock of Propanc Biopharma is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.66 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PPCB Previous Symbol CUSIPN/A CIK1517681 Webwww.propanc.com Phone610398820780Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.61) per share Price / Book0.00Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-5,760,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-7,041.18%Miscellaneous Employees1 Outstanding Shares47,090,000Market Cap$141,270.00 Next Earnings Date10/20/2020 (Estimated) OptionableNot Optionable OTC:PPCB Rates by TradingView Receive PPCB News and Ratings via Email Sign-up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter. Propanc Biopharma (OTCMKTS:PPCB) Frequently Asked Questions How has Propanc Biopharma's stock been impacted by COVID-19 (Coronavirus)? Propanc Biopharma's stock was trading at $0.0449 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PPCB shares have decreased by 93.3% and is now trading at $0.0030. View which stocks have been most impacted by Coronavirus. When is Propanc Biopharma's next earnings date? Propanc Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, October 20th 2020. View our earnings forecast for Propanc Biopharma. How were Propanc Biopharma's earnings last quarter? Propanc Biopharma Inc (OTCMKTS:PPCB) posted its quarterly earnings data on Friday, May, 15th. The company reported ($0.35) earnings per share for the quarter. View Propanc Biopharma's earnings history. Has Propanc Biopharma been receiving favorable news coverage? News headlines about PPCB stock have been trending very negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Propanc Biopharma earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Propanc Biopharma. Who are some of Propanc Biopharma's key competitors? Some companies that are related to Propanc Biopharma include Spotlight Innovation (STLT), Targeted Medical Pharma (TRGM), Sophiris Bio (SPHS), Sienna Biopharmaceuticals (SNNAQ), ProMetic Life Sciences (PFSCF), HST Global (HSTC), Skinvisible (SKVI), Orexigen Therapeutics (OREXQ), Immune Therapeutics (IMUN), 89bio (ETNB), Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI) and Anthera Pharmaceuticals (ANTH). View all competitors. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Canopy Growth (CGC), Cronos Group (CRON), Avis Budget Group (CAR), Crispr Therapeutics (CRSP), Insys Therapeutics (INSY), Bed Bath & Beyond (BBBY), Charlotte's Web (CWBHF), Delcath Systems (DCTH), General Electric (GE) and Petroteq Energy (PQEFF). Who are Propanc Biopharma's key executives? Propanc Biopharma's management team includes the following people: Mr. James Nathanielsz, Acting Chairman, CEO, CFO, Sec., Treasurer & Director (Age 45)Dr. Julian Norman Kenyon, Chief Scientific Officer & Director (Age 71)Prof. Klaus Kutz, Chief Medical Officer & Member of Scientific Advisory Board What is Propanc Biopharma's stock symbol? Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB." How do I buy shares of Propanc Biopharma? Shares of PPCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Propanc Biopharma's stock price today? One share of PPCB stock can currently be purchased for approximately $0.00. How big of a company is Propanc Biopharma? Propanc Biopharma has a market capitalization of $141,270.00. Propanc Biopharma employs 1 workers across the globe. What is Propanc Biopharma's official website? The official website for Propanc Biopharma is www.propanc.com. How can I contact Propanc Biopharma? Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The company can be reached via phone at 610398820780 or via email at irteam[email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
